You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

Claims for Patent: 9,695,150


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,695,150
Title:Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
Abstract: The present invention relates to a crystalline form of N-(3-fluoro-4-((7-(2-hydroxy-2-methylpropoxy)quinolin-4-yl)oxy)phenyl)-1,- 5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide p-toluenesulfonate, the process for preparing the crystalline form thereof, and pharmaceutical compositions comprising the crystalline form thereof. This invention also relates to a method of using such a crystalline form in the treatment of hyperproliferative diseases in mammals, especially in humans.
Inventor(s): Xi; Ning (Newbury Park, CA), Sun; Mingming (Guangdong, CN)
Assignee: CALITOR SCIENCES, LLC (Newbury Park, CA) SUNSHINE LAKE PHARMA CO., LTD. (Dongguan, Guangdong, CN)
Application Number:15/350,014
Patent Claims:1. A crystalline form of a compound of formula (I): ##STR00003## wherein the crystalline form is form C having: a) an X-ray powder diffraction pattern comprising peaks, in terms of 2.theta., at about 7.20.degree., about 10.06.degree., about 17.40.degree., about 17.75.degree., about 18.65.degree., about 19.48.degree. and about 20.13.degree.; or b) an X-ray powder diffraction pattern comprising peaks, in terms of 2.theta., at 7.20.degree..+-.0.2.degree., 10.06.degree..+-.0.2.degree., 17.40.degree..+-.0.2.degree., 17.75.degree..+-.0.2.degree., 18.65.degree..+-.0.2.degree., 19.48.degree..+-.0.2.degree. and 20.13.degree..+-.0.2.degree..

2. The crystalline form of claim 1 having an X-ray powder diffraction pattern comprising peaks, in terms of 2.theta., at about 7.20.degree., about 10.06.degree., about 14.96.degree., about 16.76, about 17.40.degree., about 17.75.degree., about 18.65.degree., about 19.48.degree., about 20.13.degree., about 20.90.degree., about 21.71.degree., about 22.69.degree., about 23.37.degree., about 24.40.degree., about 25.52.degree., about 26.29.degree. and about 28.41.degree.; or at 7.20.degree..+-.0.2.degree., 10.06.degree..+-.0.2.degree., 14.96.+-.0.2.degree., 16.76.+-.0.2.degree., 17.40.degree..+-.0.2.degree., 17.75.degree..+-.0.2.degree., 18.65.degree..+-.0.2.degree., 19.48.degree..+-.0.2.degree., 20.13.degree..+-.0.2.degree., 20.90.degree..+-.0.2.degree., 21.71.degree..+-.0.2.degree., 22.69.degree..+-.0.2.degree., 23.37.degree..+-.0.2.degree., 24.40.degree..+-.0.2.degree., 25.52.degree..+-.0.2.degree.,26.29.degree..+-.0.2.degree. and 28.41.degree..+-.0.2.degree..

3. The crystalline form of claim 1, wherein the X-ray powder diffraction pattern is substantially in accordance with that shown in FIG. 1.

4. The crystalline form of claim 1, wherein the crystalline form is substantially pure.

5. A pharmaceutical composition comprising the crystalline form of claim 1 and a pharmaceutically acceptable excipient, carrier, vehicle or a combination thereof.

6. The pharmaceutical composition of claim 5 further comprising a therapeutic agent.

7. The pharmaceutical composition of claim 6, wherein the therapeutic agent is melphalan, cyclophosphamide, ifosfamide, busulfan, carmustine, lomustine, streptozocin, cisplatin, carboplatin, oxaliplatin, dacarbazine, temozolomide, procarbazine, methotrexate, fluorouracil, cytarabine, gemcitabine, mercaptopurine, fludarabine, vinblastine, vincristine, vinorelbine, paclitaxel, docetaxel, topotecan, irinotecan, etoposide, trabectedin, dactinomycin, doxorubicin, epirubicin, daunorubicin, mitoxantrone, bleomycin, mitomycin, ixabepilone, tamoxifen, flutamide, gonadorelin analogues, megestrol, prednisone, dexamethasone, methylprednisolone, thalidomide, interferon alfa, leucovorin, sirolimus, temsirolimus, everolimus, afatinib, alisertib, amuvatinib, apatinib, axitinib, bosutinib, bortezomib, brivanib, cediranib, cabozantinib, crenolanib, crizotinib, dabrafenib, dacomitinib, danusertib, dasatinib, dovitinib, erlotinib, foretinib, ganetespib, gefitinib, ibrutinib, icotinib, imatinib, iniparib, lapatinib, lenvatinib, linifanib, linsitinib, masitinib, momelotinib, neratinib, nilotinib, niraparib, oprozomib, olaparib, pazopanib, pegaptanib, pictilisib, ponatinib, quizartinib, radotinib, regorafenib, rigosertib, rucaparib, ruxolitinib, saracatinib, saridegib, sorafenib, sunitinib, tasocitinib, telatinib, tivantinib, tivozanib, tofacitinib, trametinib, vandetanib, veliparib, vemurafenib, vismodegib, volasertib, alemtuzumab, bevacizumab, brentuximabvedotin, catumaxomab, cetuximab, denosumab, gemtuzumab, ipilimumab, nimotuzumab, ofatumumab, panitumumab, ramucirumab, rituximab, tositumomab, trastuzumab, idelalisib, duvelisib, gilteritinib, buparlisib, taselisib, copanlisib, voxtalisib, pilaralisib, sonolisib, perifosine, alectinib, ibrutinib, pertuzumab, nintedanib, cobimetinib, temsirolimus, sirolimus, pixantrone or a combination thereof.

Details for Patent 9,695,150

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 11/26/1997 ⤷  Try a Trial 2035-11-14
Idec Pharmaceuticals Corp. RITUXAN rituximab Injection 103737 02/19/2002 ⤷  Try a Trial 2035-11-14
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 09/25/1998 ⤷  Try a Trial 2035-11-14
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 02/10/2017 ⤷  Try a Trial 2035-11-14
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 05/07/2001 ⤷  Try a Trial 2035-11-14
Genzyme Corporation LEMTRADA alemtuzumab Injection 103948 11/14/2014 ⤷  Try a Trial 2035-11-14
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 10/12/2004 ⤷  Try a Trial 2035-11-14
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.